Squarepoint’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $555K | Buy |
390,583
+41,666
| +12% | +$59.2K | ﹤0.01% | 1854 |
|
|
2025
Q1 | $534K | Buy |
348,917
+56,025
| +19% | +$85.7K | ﹤0.01% | 1871 |
|
|
2024
Q4 | $726K | Buy |
292,892
+152,312
| +108% | +$378K | ﹤0.01% | 1726 |
|
|
2024
Q3 | $162K | Buy |
140,580
+45,893
| +48% | +$52.8K | ﹤0.01% | 2239 |
|
|
2024
Q2 | $104K | Buy |
+94,687
| New | +$104K | ﹤0.01% | 2256 |
|
|
2024
Q1 | – | Sell |
-10,378
| Closed | -$10.9K | – | 2391 |
|
|
2023
Q4 | $10.9K | Buy |
+10,378
| New | +$10.9K | ﹤0.01% | 2441 |
|
|
2021
Q4 | – | Sell |
-15,834
| Closed | -$285K | – | 2500 |
|
|
2021
Q3 | $285K | Buy |
+15,834
| New | +$285K | ﹤0.01% | 1657 |
|
|
2021
Q2 | – | Sell |
-8,537
| Closed | -$215K | – | 2565 |
|
|
2021
Q1 | $215K | Buy |
+8,537
| New | +$215K | ﹤0.01% | 2121 |
|
|
2020
Q1 | – | Sell |
-83,924
| Closed | -$159K | – | 1791 |
|
|
2019
Q4 | $159K | Buy |
+83,924
| New | +$159K | ﹤0.01% | 2177 |
|
|
2019
Q3 | – | Sell |
-58,902
| Closed | -$129K | – | 2195 |
|
|
2019
Q2 | $129K | Buy |
58,902
+12,996
| +28% | +$28.5K | ﹤0.01% | 2117 |
|
|
2019
Q1 | $275K | Sell |
45,906
-66,684
| -59% | -$399K | ﹤0.01% | 1763 |
|
|
2018
Q4 | $832K | Buy |
112,590
+81,220
| +259% | +$600K | 0.01% | 983 |
|
|
2018
Q3 | $455K | Buy |
31,370
+16,995
| +118% | +$247K | 0.01% | 1342 |
|
|
2018
Q2 | $287K | Sell |
14,375
-24,683
| -63% | -$493K | ﹤0.01% | 1395 |
|
|
2018
Q1 | $684K | Buy |
39,058
+19,442
| +99% | +$340K | 0.01% | 961 |
|
|
2017
Q4 | $484K | Buy |
+19,616
| New | +$484K | 0.01% | 1221 |
|
|
2017
Q1 | – | Sell |
-10,739
| Closed | -$291K | – | 1478 |
|
|
2016
Q4 | $291K | Buy |
+10,739
| New | +$291K | 0.01% | 1167 |
|